Search PubMed⌕ Search

Biomedical subjects

H C Neu

Publications and source records attributed to H C Neu.

At least 433 records · Page 24Linked to original sources
PubMed1975

Aminopenicillins - clinical pharmacology and use in disease states.

Ampicillin introduced in 1961 has been administered in the treatment of diverse infections by both oral and parenteral means. Oral infections of the upper airways such as otitis media, bronchitis, and pneumonia have responded with high success rates since the microorganisms involved have remained sensitive to ampicillin. Similarly, out-patient urinary tract infections caused by Escherichia coli, Proteus mirabilis, and enterococci are cured. Typhoid fever may yet be treated with ampicillin, but shigellosis has become refractory with the development of resistant strains. Ampicillin has assumed a prominent role in the treatment of gonorrhoea. Parenteral ampicillin is still a mainstay of the treatment of Hemophilus meningitis, but the recent appearance of ampicillin resistant strains may become a serious problem. A number of derivatives and analogues of ampicillin have been developed. Among the compounds, hetacillin, metampicillin and pivampicillin which hydrolyze in the body to yield ampicillin, only pivampicillin appears to offer advantage over the parent compound. Blood levels are twice those of a comparable dose of ampicillin. However, more comparisons with ampicillin in clinical situations are needed. The other analogues of ampicillin are epicillin, cyclacillin and amoxicillin. Epicillin has no superiority to ampicillin, and the cyclacillin data do not show clear superiority over ampicillin in spite of initially high blood levels, since the compound is less active and so rapidly cleared from the body. Amoxicillin, on the other hand, has been shown to have it vitro activity equal to ampicillin and to produce higher blood levels for a longer period of time. Clinical studies have substantiated efficacy in treatment of otitis media, pharyngitis, bronchitis, pneumonitis, and urinary tract infections at doses half those of ampicillin. It has been effective in gonorrhoea and typhoid, but not in shigellosis. It would seem that to date only pivampicillin and amoxicillin, particularly the later, should be considered as replacements of ampicillin in oral therapy.

Acetamides↗
PubMed1974

Relation of cell wall lipid content of Serratia marcescens to resistance to antimicrobial agents.

Serratia marcescens strains were divided into three groups on the basis of antimicrobial sensitivity and pigment production. Group I, nonpigmented, was resistant to most antibiotics. Group II, nonpigmented, was susceptible to many antimicrobial agents, as was group III which was pigmented. Representative organisms of each group were examined for all lipid content. There were no significant differences in total lipid, phospholipid, or fatty acid esters among the three groups. Differences in susceptibility to antibiotics in Serratia do not seem to be explained on the basis of wall lipid content.

Anti-Bacterial Agents↗
PubMed1974

Cefoxitin, a semisynthetic cephamycin antibiotic: antibacterial spectrum and resistance to hydrolysis by gram-negative beta-lactamases.

The in vitro activity of cefoxitin, 3-carbamolyloxymethyl-7-alpha-methoxy-7[2-(2-thienyl)acetamido]-3-cephem-4-carboyxlic acid, was investigated. Activity against gram-positive organisms was less than that of cephalothin and cephloridine. It was highly active against gram-negative bacilli, with activity against Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae equal to that of currently available cephalosporins. In addition, it was active against certain Enterobacter strains, Serratia marcescens, indole-positive Proteae and Herellea. The strains of these latter bacteria were strains susceptible to carbenicillin and ticarcillin. Pseudomonas aeruginosa and other Pseudomonas species were resistant. Changes in pH, inoculum size, and type of growth medium had no significant effect on the activity of the antibiotic. Cefoxitin was highly resistant to hydrolysis by various types of gram-negative beta-lactamases. The precise role of resistance to beta-lactamase hydrolysis varied from strain to strain. Bacterial resistance to cefoxitin was not necessarily related to hydrolysis of the antibiotic. However, the resistance of cefoxitin to hydrolysis did contribute to its activity. Cefoxitin could function as an inducer of beta-lactamase activity and effectively bound to purified beta-lactamases.

Anti-Bacterial Agents↗
PubMed1974

Cefamandole, a cephalosporin antibiotic with an unusually wide spectrum of activity.

The in vitro activity of cefamandole, 7-d-mandelamido-3-(1 methyl-1H-tetrazol-5 yethiomethyl)-3-cephem-4 carboxylic acid, was investigated. The majority of streptococci and pneumococci were inhibited by 0.1 mug/ml. Activity against Staphylococcus aureus was below that of cephalothin, but most strains were inhibited by 0.4 mug/ml. Enterococci were not inhibited by less than 25 mug/ml. Cefamandole was very active against most members of the Enterobacteriaceae, with 70% of Escherichia coli, 86% of Klebsiella pneumoniae, and 88% of Proteus mirabilis inhibited by 1.6 mug/ml. A number of Enterobacter aerogenes, Proteus vulgaris, and Serratia marcescens strains were inhibited by less than 25 mug/ml. Pseudomonas species were resistant. Cefamandole was more active than cephalothin, cephaloridine, or cephalexin against members of the Enterobacteriaceae. Inoculum size and type of medium had variable effects on the minimal inhibitory concentration, depending upon the particular strain tested. Strains of Enterobacter, Serratia, indole-positive Proteus species showed the greatest inoculum effect. Similarly, these species showed a several-fold difference of bactericidal and inhibitory levels. Resistance of cefamandole to hydrolysis by gram-negative beta-lactamase played a partial role in its activity, but some strains that hydrolyzed the agent were susceptible.

Anti-Bacterial Agents↗
PubMed1973

Newer antibiotics.

Explore the source record for details and available documents.

Anti-Bacterial Agents↗
PubMed1973

Interbacterial transfer of R factor in humans.

In vivo interbacterial transfer of R factor was observed in two patients. Resistance to ampicillin, tetracycline, streptomycin, and chloramphenicol was transferred from Escherichia coli in the intestine of a patient with shigellosis to a Shigella sonnei strain. In a second patient with partial ureteral obstruction, a resistant E. coli strain transferred ampicillin, tetracycline, and streptomycin resistance to a Proteus mirabilis strain.

Adolescent↗